Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements within the GlaxoSmithKline Employee Trust ("GSK Trust") during November 2005:
- November 1, 2005: The GSK Trust sold 1,718 Ordinary Shares on behalf of participants in the SmithKline Beecham Mid-Term Incentive Plan at GBP 14.6636 per share.
- November 16, 2005: The GSK Trust transferred 9,005 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- November 17, 2005: The GSK Trust transferred 2,470 Ordinary Shares to participants in the SmithKline Beecham Mid-Term Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.
Key Facts for Investor Verification
- Verify the total number of shares transferred or sold by the GSK Trust in November 2005 (12,193 shares total).
- Confirm the transaction price of GBP 14.6636 per share for the November 1 sale.
- Identify the specific incentive plans involved: SmithKline Beecham Mid-Term Incentive Plan and SmithKline Beecham Employee Share Option Plan 1991.
- Note that this filing does not reflect operational or financial performance for the period.